The great majority of new, innovative medicines and vaccines marketed in the EU go through the centralized procedure, which includes scientific assessment by European Medicines Agency’s human medicines committee (the CHMP) and then a final decision by the European Commission. Decisions are valid in all EU member states as well as in the European Economic Area countries of Iceland, Liechtenstein and Norway. They are also valid in Northern Ireland under the provisions of the Northern Ireland Protocol.
Click on any column header to sort by that topic. The search box can be used to filter results.
